Wegovy cuts BMI 17.4% in kids 6-12, trial shows

Picture of Sandra Oparaocha

Sandra Oparaocha

Wegovy cuts BMI 17.4% in kids 6-12, trial shows

Novo Nordisk published full Phase 3 results on Monday showing that semaglutide, the active ingredient in Wegovy, cut BMI by 17.4 percent in children aged 6 to 12 with severe obesity.

According to reporting by DR, the Danish pharmaceutical company released the findings on Monday, November 16, in a company statement. The trial, named STEP Young, tested weekly injections in children aged 6 to 12 with severe obesity.

The treatment was combined with a reduced-calorie diet and increased physical activity. After 68 weeks, BMI had fallen by an average of 17.4 percent in the children who received semaglutide, DR reports. Among the children who did not receive the drug, BMI rose by 2.2 percent.

Novo also reported that 40.4 percent of children in the semaglutide group were no longer classified as having severe obesity at the end of the treatment period. In the placebo group, that share was zero percent. BMI, or body mass index, describes the ratio between a person’s weight and height and is used as an indicator of overweight.

What the numbers cover, and where sources differ

DR states that 167 children took part in the study, which began in July 2023 and finished in July this year. Novo Nordisk’s own release and the New England Journal of Medicine put enrolment at 165. The journal also reports a second calculation covering all enrolled children regardless of whether they stayed on treatment, which shows a 13.5 percent BMI reduction on semaglutide and a 2.7 percent rise on placebo.

The trial is listed on the public registry ClinicalTrials.gov under the number NCT05726227 as a Novo Nordisk sponsored study, with its status verified in October 2026. Per the journal, the study was randomized, double-blind and placebo-controlled, and both groups received lifestyle support. Novo’s head of research and development, Martin Holst Lange, said in the company statement that obesity can have lifelong consequences when it starts in childhood.

Lange added that many children and young people still lack access to comprehensive treatment, from prevention and lifestyle change to medical treatment where it is clinically relevant and approved. Proinvestor notes that 83 percent of the children on semaglutide lost weight, against 23.5 percent on placebo. TV2 Østjylland carried the figures as a Ritzau brief on Monday.

Why the results landed this week

Per Proinvestor, the full results were presented at the ObesityWeek 2026 conference and printed in the New England Journal of Medicine. CNBC reports that Wegovy is already approved for obesity in children aged 12 and older, while no medication is approved for those under 12.

What it means for parents in Denmark

In Denmark, Wegovy is a prescription medicine, and DR states that children from the age of 12 can currently be prescribed it. Prescriptions normally start with your family doctor, the egen læge you are assigned through your CPR registration, which is also the entry point to the rest of healthcare in Denmark. A trial result is not an approval, and no medication is approved for children under 12.

No statement from the Danish Medicines Agency, Lægemiddelstyrelsen, or from Medicinrådet on the STEP Young results was available at the time of publication. That means there is no Danish decision, timeline or price for use in children under 12 to report. Earlier coverage of the adult market has pointed to practical questions around long-term use, including reporting that 49 percent of Danish Wegovy users quit within a year.

author avatar
Sandra Oparaocha Writer
Sandra Oparaocha covers Danish politics for The Danish Dream, following the latest political news and explaining what it means for internationals living in Denmark.
Salling Group: Redefining Danish Retail Strategically

Get the daily top News Stories from Denmark in your inbox